Regeneron Pharmaceuticals (REGN) revenue in Q3 was 5.12 billion USD (+36.3% y/y), and earnings per share (GAAP) increased to 18.45 USD (+35.5% y/y).

Quarterly results#

Earnings per share (GAAP, basic) reached 19.16 USD (+36.0% y/y), while earnings per share (adjusted) increased by 69.7% y/y to 20.07 USD. The company’s operating income was 2.05 billion USD, representing an increase of 99.5% y/y compared to 1.03 billion USD a year earlier.

What management says#

Management emphasized that relations with partner Sanofi are very good, and the cooperation is on a strong track and open to new projects. According to management, the company is open to acquisitions and licenses at every stage of drug development, however, science decides the decisions. Management noted that when comparing external opportunities with their own research department, their own projects are usually selected. According to management, preparations for introducing a new drug for myasthenia are highly advanced. Management also emphasized that when entering new areas, such as obesity treatment, the company aims for solutions that realistically change the situation for patients, rather than just more similar drugs.